JP2011509676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509676A5 JP2011509676A5 JP2010543306A JP2010543306A JP2011509676A5 JP 2011509676 A5 JP2011509676 A5 JP 2011509676A5 JP 2010543306 A JP2010543306 A JP 2010543306A JP 2010543306 A JP2010543306 A JP 2010543306A JP 2011509676 A5 JP2011509676 A5 JP 2011509676A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- composition
- blt1
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims description 56
- 210000000068 Th17 cell Anatomy 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 44
- 238000002405 diagnostic procedure Methods 0.000 claims description 42
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 claims description 29
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 claims description 29
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 claims description 29
- 102100037265 Podoplanin Human genes 0.000 claims description 28
- 101710118150 Podoplanin Proteins 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 27
- 239000005557 antagonist Substances 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 26
- 208000023275 Autoimmune disease Diseases 0.000 claims description 22
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 22
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 22
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 22
- 102000013691 Interleukin-17 Human genes 0.000 claims description 18
- 230000004069 differentiation Effects 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 1
- 238000004163 cytometry Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US654108P | 2008-01-18 | 2008-01-18 | |
| US3182408P | 2008-02-27 | 2008-02-27 | |
| PCT/US2009/031477 WO2009092087A2 (en) | 2008-01-18 | 2009-01-21 | Selective differentiation, identification, and modulation of human th17 cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509676A JP2011509676A (ja) | 2011-03-31 |
| JP2011509676A5 true JP2011509676A5 (enExample) | 2013-02-28 |
Family
ID=40885916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543306A Pending JP2011509676A (ja) | 2008-01-18 | 2009-01-21 | ヒトＴｈ１７細胞の選択的分化、同定および調節 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110245107A1 (enExample) |
| EP (1) | EP2238241B1 (enExample) |
| JP (1) | JP2011509676A (enExample) |
| WO (1) | WO2009092087A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| WO2008115290A2 (en) | 2006-10-25 | 2008-09-25 | Revalesio Corporation | Methods of wound care and treatment |
| US8784898B2 (en) * | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
| EP2086668B1 (en) | 2006-10-25 | 2016-11-16 | Revalesio Corporation | Mixing device and method |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| AU2007308840C1 (en) | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| US20100310609A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Compositions and methods for treatment of neurodegenerative diseases |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) * | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US20100004189A1 (en) * | 2007-10-25 | 2010-01-07 | Revalesio Corporation | Compositions and methods for treating cystic fibrosis |
| US20100008997A1 (en) * | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US20100303871A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| BRPI0911757A2 (pt) | 2008-05-01 | 2013-09-17 | Revalesio Corp | composiÇÕes e mÉtodos para tratar distérbios digestivos. |
| US20100098687A1 (en) * | 2008-10-22 | 2010-04-22 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| JP5858785B2 (ja) * | 2009-07-29 | 2016-02-10 | シスメックス株式会社 | ヒトｉｌ−１７産生ヘルパーｔ細胞検出用マーカーおよび試薬、並びにヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法 |
| US20130017188A1 (en) * | 2009-07-31 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| JP5481677B2 (ja) * | 2009-12-10 | 2014-04-23 | シャープ株式会社 | 生体内に蓄積した粒子の分析方法 |
| BR112012028540A2 (pt) | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| WO2011152503A1 (ja) * | 2010-06-02 | 2011-12-08 | 大日本住友製薬株式会社 | 自己免疫疾患またはアレルギー疾患の治療剤 |
| FR2960882B1 (fr) * | 2010-06-04 | 2012-11-16 | Hospices Civils Lyon | Co-culture de cellules mononucleees et de cellules mesenchymateuses pour l'obtention de cellules productrices d'il-17 |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| KR20140020321A (ko) * | 2011-04-13 | 2014-02-18 | 레발레시오 코퍼레이션 | 염증성 신경변성 질환에 관여하는 작동자 ｔ 세포를 억제하고／하거나 조절하기 위한 조성물 및 방법 |
| EP2723361B1 (en) | 2011-06-22 | 2019-10-30 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| JP2016525873A (ja) | 2013-02-27 | 2016-09-01 | ザ・ブロード・インスティテュート・インコーポレイテッド | Ｔ細胞バランス遺伝子発現、組成物およびその使用方法 |
| KR102405247B1 (ko) * | 2013-07-23 | 2022-06-07 | 바이오콘 리미티드 | Cd6 결합 파트너의 용도 및 이에 기초한 방법 |
| AU2014308751B2 (en) | 2013-08-22 | 2020-03-05 | Acceleron Pharma, Inc. | TGF-beta receptor type II variants and uses thereof |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| BR112019023071A2 (pt) | 2017-05-04 | 2020-06-09 | Acceleron Pharma Inc | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas |
| WO2020102623A1 (en) * | 2018-11-15 | 2020-05-22 | The University Of Toledo | Materials and methods for the prevention of rheumatoid arthritis |
| TW202144400A (zh) * | 2020-02-20 | 2021-12-01 | 美商凱特製藥公司 | 嵌合抗原受體t細胞療法 |
| US20230323296A1 (en) * | 2020-08-21 | 2023-10-12 | Georgetown University | Stem cell-like memory t cells and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| MXPA04004167A (es) | 2001-11-05 | 2004-07-08 | Zymogenetics Inc | Antagonistas de interleucina-21. |
| US7622443B2 (en) * | 2002-04-26 | 2009-11-24 | California Institute Of Technology | Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides |
| CN1688340A (zh) | 2002-07-15 | 2005-10-26 | 韦思公司 | 调节t辅助(th)细胞发育和功能的方法和组合物 |
| EP1633718B1 (en) | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| GB0410103D0 (en) * | 2004-05-06 | 2004-06-09 | Biolipox Ab | New method |
| JP2008505080A (ja) * | 2004-07-01 | 2008-02-21 | ニューヨーク ユニバーシティー | ＲＯＲγｔ機能の調節のための組成物および方法 |
| CN101472611A (zh) * | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| CA2657649A1 (en) * | 2006-07-13 | 2008-08-21 | Burnham Institute For Medical Research | Methods and compositions for targeting gc1qr/p32 |
| KR101078889B1 (ko) * | 2007-03-23 | 2011-11-01 | 고려대학교 산학협력단 | 인간의 암 치료를 위한 류코트리엔 ｂ4 수용체 ｂｌｔ2의 저해제의 용도 |
| US20110136113A1 (en) * | 2008-08-27 | 2011-06-09 | Sysmex Corporation | Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helper t cell |
-
2009
- 2009-01-21 US US12/863,373 patent/US20110245107A1/en not_active Abandoned
- 2009-01-21 JP JP2010543306A patent/JP2011509676A/ja active Pending
- 2009-01-21 WO PCT/US2009/031477 patent/WO2009092087A2/en not_active Ceased
- 2009-01-21 EP EP09702239.6A patent/EP2238241B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017202172B2 (en) | New Th17 differentiation markers for acne and uses thereof | |
| JP2012085556A (ja) | 乳がんの診断方法 | |
| JP2009284907A (ja) | 膵癌の診断および治療のための方法、ならびにそれらに有用な組成物 | |
| US20140141985A1 (en) | Biomarkers of therapeutic responsiveness | |
| JP2021502069A5 (enExample) | ||
| WO2023079150A1 (en) | Biomarker panel for diagnosing pulmonary dysfunction | |
| CN111060694B (zh) | 一种用于血管炎性高血压联合诊断试剂盒及其应用 | |
| JP2012085554A (ja) | 乳がんのサブタイプの判別方法 | |
| KR101815253B1 (ko) | 간 섬유화 진단용 바이오마커 cxcl14 | |
| JP2021170021A (ja) | 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法 | |
| EP2895863B1 (en) | New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma | |
| CN112285360A (zh) | I-309在制备原发性干燥综合征诊断试剂或试剂盒中的应用 | |
| JP2012085555A (ja) | 乳がん診断用マーカー | |
| CN112485448B (zh) | Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用 | |
| Karatolios et al. | Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions | |
| US12590958B2 (en) | Assessing responsiveness of rheumatoid arthritis patients to biological treatment | |
| CN114994327A (zh) | 一种生物标志物gsdme的应用 | |
| JP6306124B2 (ja) | 結核検査用バイオマーカー | |
| US20250264456A1 (en) | System and method for biomolecule detection | |
| JP2022025456A (ja) | 多発性硬化症を検査する方法 | |
| JP6083784B2 (ja) | 慢性閉塞性肺疾患の増悪指標の検出方法 | |
| JP2020516301A (ja) | 骨髄応答および免疫応答の予測のためのｓｈ２ｂアダプタータンパク質３ | |
| JP2026502556A (ja) | エクソソームを用いた扁平上皮細胞肺癌の診断又は予後予測用バイオマーカー及びその用途 | |
| WO2025179216A1 (en) | Methods and materials to distinguish between active eosinophilic esophagitis (eoe), eoe in remission, and non-eoe states | |
| JP2012088221A (ja) | Ｇｉｓｔの診断方法 |